stockrowRedhill Biopharma Ltd.
RDHL Healthcare Drug Manufacturers Specialty & Generic
Redhill Biopharma Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $286,000.00, down 96.4% from fiscal 2024.
Follow RDHL
Alert me
Redhill Biopharma Ltd. (RDHL) EV/Sales
As of 5 November 2026, Redhill Biopharma Ltd. (RDHL) trades at a EV/Sales of 6.4×. Over the past ten years it has ranged from 1.1× (June 2022) to 39,788× (August 2016); the current reading is higher than 38% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.9× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.5× | 2.38% |
| FY2024 | 6.4× | 3.14% |
| FY2023 | 6.2× | 113.01% |
| FY2022 | 2.9× | 48.24% |
| FY2021 | 1.9× | (63.88%) |
| FY2020 | 5.4× | (75.07%) |
| FY2019 | 21.7× | 141.30% |
| FY2018 | 9.0× | (17.36%) |
| FY2017 | 10.9× | (98.36%) |
| FY2016 | 660× | (97.61%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2023 | 18.9× | (27.20%) |
| Mar 2023 | 25.9× | 796.16% |
| Dec 2022 | 2.9× | 9.53% |
| Sep 2022 | 2.6× | 18.78% |
| 26 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SXTC China SXT Pharmaceuticals, Inc. compare | −5.9× |
| SNOA Sonoma Pharmaceuticals, Inc. compare | 0.0× |
| GELS Gelteq Limited compare | n/m |
| AKAN Akanda Corp. compare | n/m |
| APUS Apimeds Pharmaceuticals US, Inc. compare | n/m |
| PRFX PainReform Ltd. compare | n/m |
| YCBD cbdMD, Inc. compare | 0.2× |
| RDHL Redhill Biopharma Ltd. | 6.4× |
| BTAIQ BioXcel Therapeutics, Inc. compare | 228× |
| Drug Manufacturers Specialty & Generic industry median | 2.9× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)